Bristol–Myers Squibb was invited to submit evidence for this single technology appraisal for elotuzumab in December 2015.
Elotuzumab is used in combination with lenalidomide and dexamethasone. The ELOQUENT-2 clinical trial showed a favourable efficacy and safety profile of this regimen compared with lenalidomide plus dexamethasone.
The company was unable to show that the additional survival benefit or the improvements in quality of life associated with this combination were sufficient to warrant the increased cost to the NHS of funding all 3 drugs, as determined by the NICE cost-effectiveness threshold.
NICE has therefore terminated this single technology appraisal.